Citations

Clear

26 citation(s) found for "Thibault, C".

Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring.
Assénat, Eric , Képénékian, Vahan , Dupuy, Marie , Liaud, Pierre, Mazard, Thibault , Ferron, Gwénaël , Flacelière, Maud, Soulé, Julien, Saywell, Véronique, Tan, Winston , Villeneuve, Laurent , Beloin, Fanny, Joubert, Dominique , Prieur, Alexandre , You, Benoît , Gléhen, Olivier , Maucort‐Boulch, Delphine , Payen, Léa , Ychou, Marc , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3037-3037

10.1200/jco.2019.37.15_suppl.3037 Get It

3037 Background: The successes of recent publications on “multi-tumor” circulating markers highlight the relevance of novel universal diagnostic cancer serum biomarkers. Since the Wnt/ß-catenin/Tcf4 pathway, activated in many tumors, induces the GAST Gene encoding progastrin synthesis, we hypothesized that progastrin, easily measurable in the blood, might be a “multi-tumor” diagnostic biomarker. Methods: Progastrin levels were measured in the blood samples of 1319 patients with 12 different cancer origins, and compared to those of 557 asymptomatic 18-75 years old blood donors. Moreover the longitudinal kinetics of progastrin concentrations were serially assessed during treatments in 168 patients with ovarian cancers enrolled in the randomized CHIVA trial (NCT01583322, GINECO), 191 patients with peritoneal involvement from gastro-intestinal cancers enrolled in BIG-RENAPE trial (NCT03787056), and in 95 HCC patients. The progastrin was measured using an ELISA test developed by ECS Progastrin (Prilly, Switzerland). Results: Compared to healthy blood donors, progastrin was found at higher concentrations in the plasma of cancer patients: median 4.47 vs 0.20 pM, P < 0.0001; diagnostic discriminative power, ROC analysis AUC = 0.86 (95% CI, 0.83-0.89; P < 0.0001). Progastrin levels were found elevated in all cancer groups, regardless of disease stages, and of pathology origins: ROC AUCs ranged from 0.71 to 0.93, all P < 0.0001 (Table). The longitudinal progastrin changes during treatments, suggest relationships to tumor burden, and potential monitoring value. Conclusions: Progastrin is a novel ubiquitous cancer biomarker, easily detectable in the blood using an affordable ELISA test (CancerRead Lab test(R)). It may change the future paradigms about screening (in particular for populations at higher or lower risks of cancer), cancer diagnostic & monitoring. [Table: see text]
Biomechanical Comparison of Anatomic and Extra-Anatomic Reconstruction Techniques Using Local Grafts for Chronic Instability of the Acromioclavicular Joint
Thoreson, Andrew R. , Delgrande, Damien, Lafosse, Thibault , Werthel, Jean-David , Hardy, P., Elhassan, Bassem T. , Le Hanneur, Malo, Thoreson, Andrew, Elhassan, Bassem, Hanneur, Malo Le

Mayo Clinic

The American Journal of Sports Medicine | May 10, 2018 | Volume: 46 | Issue: 8 | Pages: 1927-1935

10.1177/0363546518770603 | PMID 29746150 Get It

Background: Anatomic reconstruction techniques are increasingly used to address cases of acromioclavicular (AC) joint chronic instability. These usually involve an additional surgical site for autograft harvesting or an allograft. Purpose: To describe a triple-bundle (TB) anatomic reconstruction using on-site autografts, the semiconjoint tendon (SCT) and the coracoacromial ligament (CAL), and compare its primary stability to the native AC joint ligamentous complex and to a modified Weaver-Dunn (WD) reconstruction. Study Design: Controlled laboratory study. Methods: Intact AC joints of 12 paired cadaveric shoulders were tested for anterior, posterior, and superior translations under cyclic loading with a servo-hydraulic testing system. One shoulder from each pair was randomly assigned to the TB group, where 2 SCT strips were used to reconstruct the coracoclavicular ligaments while the distal end of the CAL was transferred to the distal extremity of the clavicle to reconstruct the AC ligaments; the other shoulder received a modified WD reconstruction. After reconstruction, the same translational testing was performed, with an additional load-to-failure test in the superior direction. Results: In both the TB and the WD groups, no significant differences were found before and after reconstruction in terms of joint displacements after cyclic loading, in all 3 directions. Compared with the WD reconstruction, the TB repair resulted in significantly lower displacements in both the anterior (ie, 2.59 ± 1.08 mm, P = .011) and posterior (ie, 10.17 ± 6.24 mm, P = .014) directions, but not in the superior direction. No significant differences were observed between the 2 reconstructions during the load-to-failure testing, except for the displacement to failure, which was significantly smaller (ie, 5.34 ± 2.97 mm) in the WD group ( P = .037). Conclusion: Anterior, posterior, and superior displacements after an anatomic reconstruction of the AC joint complex using the SCT and CAL as graft material were similar to those of native AC joints and significantly smaller in the axial plane than those of AC joints after a WD repair. Clinical Relevance: An anatomic reconstruction is achievable using the CAL and the SCT as on-site graft materials, providing satisfactory initial stability and thereby allowing earlier mobilization.
Effects of Administration of Intravenous Naloxone on Gas Exchange in Brain-Dead Lung Donors
Eagan, Christina, Keller, Cesar A., Baz, Maher A. , Thibault, Michael

Mayo Clinic

Progress in Transplantation | July 17, 2017 | Volume: 19 | Issue: 3 | Pages: 267-271

10.1177/152692480901900313 | PMID 19813490 Get It

Objective To observe the effect of naloxone on the lung function of potential lung transplant donors with neurogenic pulmonary edema. Design and Interventions Donors aged 16 to 55 years without any factors to contraindicate lung donation (pneumonia, pulmonary contusion, etc) were included. Ventilator settings were standardized to a tidal volume of 10 to 12 mL/kg, an FiO 2 of 0.40, and a respiratory rate that kept PCO 2 between 35 and 45 mm Hg. Chest physiotherapy, nebulizer treatments, and frequent suctioning were undertaken. Baseline arterial blood gas analysis and an oxygen challenge were performed. The patients were then given 8 to 10 mg of naloxone. Oxygen challenges and arterial blood gas analyses were repeated every 4 to 6 hours. The data were analyzed by using a paired t test, and each patient served as his or her own control. Setting These interventions were performed on the 19 LifeQuest donors who met the set criteria from July 2002 to July 2004. Results The PaO 2 on the oxygen challenge immediately after administration of naloxone increased from 329 (SD 177) to 363 (SD 191) mm Hg, although the increase from baseline was not significant. The PaO 2 from the second oxygen challenge (median time, 7 hours after administration of naloxone) increased to 413 (SD 177) mm Hg ( P < .01).
An Analytical Model of Traumatic Diffuse Brain Injury
Thibault, L. E., Margulies, Susan Sheps

Mayo Clinic

Journal of Biomechanical Engineering | June 12, 2009 | Volume: 111 | Issue: 3 | Pages: 241-249

10.1115/1.3168373 | PMID 2779190 Get It

Diffuse axonal injury (DAI) with prolonged coma has been produced in the primate using an impulsive, rotational acceleration of the head without impact. This pathophysiological entity has been studied subsequently from a biomechanics perspective using physical models of the skull-brain structure. Subjected to identical loading conditions as the primate, these physical models permit one to measure the deformation within the surrogate brain tissue as a function of the forces applied to the head. An analytical model designed to approximate these experiments has been developed in order to facilitate an analysis of the parameters influencing brain deformation. These three models together are directed toward the development of injury tolerance criteria based upon the shear strain magnitude experienced by the deep white matter of the brain. The analytical model geometry consists of a rigid, right-circular cylindrical shell filled with a Kelvin-Voigt viscoelastic material. Allowing no slip on the boundary, the shell is subjected to a sudden, distributed, axisymmetric, rotational load. A Fourier series representation of the load allows unrestricted load-time histories. The exact solution for the relative angular displacement (V) and the infinitesimal shear strain (ε) at any radial location in the viscoelastic material with respect to the shell was determined. The strain response for brain tissue (μ = 345 Poise, G = 1.38 × 104 Pa) was examined at the non-dimensional radial location R = 0.3. The size (1.8<R0<6.8 cm) and constitutive properties of the brain, and the magnitude, duration (2<TD<100 msec) and waveform (sine, square, triangle) of the applied load were varied independently; each contributed to the response of the tissue. Strain increased linearly with increasing magnitude of the applied load and exponentially with increasing brain size (where the exponent n was frequency-dependent). Peak angular acceleration (Θ¨p) and peak angular velocity (ΔΘ˙p) were defined as appropriate load descriptors. As ΔΘ˙p increased, strain rose rapidly and was independent of Θ¨p, then levelled off and was highly sensitive to Θ¨p.
Multiple Ipsilateral Renal Tumors Discovered At Planned Nephron Sparing Surgery: Importance of Tumor Histology and Risk of Metachronous Recurrence
Blute, Michael L., Thibault, Gregory P., Leibovich, Bradley C. , Cheville, John C. , Lohse, Christine M. , Zincke, Horst

Mayo Clinic

Journal of Urology | November 18, 2003 | Volume: 170 | Issue: 3 | Pages: 760-763

10.1097/01.ju.0000081422.47894.e6 | PMID 12913692 Get It

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Karp, Judith E. , Kaufmann, Scott H. , End, David W., Wright, John J., Bol, Kees, Horak, Ivan D. , Tidwell, Michael L., Kottke, Timothy, Ange, Dawn, Buddharaju, Laxmi Narayana, Gojo, Ivana , Highsmith, W. Edward, Belly, R. T., Hohl, Raymond J., Rybak, Mary Ellen, Thibault, Alain , Rosenblatt, Joseph D. , Lancet, Jeffrey E. , Wright, John J., Liesveld, Jane L. , Kaufmann, Scott H

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 11 | Pages: 3361-3369

10.1182/blood.v97.11.3361 | PMID 11369625 Get It

R115777 is a nonpeptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity in preclinical models. This study was a phase 1 trial of orally administered R115777 in 35 adults with poor-risk acute leukemias. Cohorts of patients received R115777 at doses ranging from 100 mg twice daily (bid) to 1200 mg bid for up to 21 days. Dose-limiting toxicity occurred at 1200 mg bid, with central neurotoxicity evidenced by ataxia, confusion, and dysarthria. Non–dose-limiting toxicities included reversible nausea, renal insufficiency, polydipsia, paresthesias, and myelosuppression. R115777 inhibited FT activity at 300 mg bid and farnesylation of FT substrates lamin A and HDJ-2 at 600 mg bid. Extracellular signal-regulated kinase (ERK), an effector enzyme of Ras-mediated signaling, was detected in its phosphorylated (activated) form in 8 (36.4%) of 22 pretreatment marrows and became undetectable in 4 of those 8 after one cycle of treatment. Pharmacokinetics revealed a linear relationship between dose and maximum plasma concentration or area under the curve over 12 hours at all dose levels. Weekly marrow samples demonstrated that R115777 accumulated in bone marrow in a dose-dependent fashion, with large increases in marrow drug levels beginning at 600 mg bid and with sustained levels throughout drug administration. Clinical responses occurred in 10 (29%) of the 34 evaluable patients, including 2 complete remissions. Genomic analyses failed to detect N-ras gene mutations in any of the 35 leukemias. The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity.